Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 13/20 | 0.43 |
| ▸ | CCND1 | P24385 | 11/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 8/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686224 | 0.93 | CCND1 (0.43) | CDK6CCND1CDK2CDK1CNR2 | |
| SCHEMBL20744010 | 0.88 | CDK1 (0.44) | CDK6CCND1CDK2CDK1CNR2 | |
| SCHEMBL20744900 | 0.84 | CNR2 (0.42) | CDK6CCND1CDK2CDK1CNR2 | |
| SCHEMBL23296207 | 0.83 | IDH1 (0.40) | CDK6CCND1CDK2CDK1CNR2 | |
| SCHEMBL20744557 | 0.80 | CCND1 (0.54) | CDK6CCND1CDK2CDK1CDK4 | |
| SCHEMBL20750918 | 0.79 | CCND1 (0.42) | CDK6CCND1CDK2CNR2CDK4 | |
| SCHEMBL23296201 | 0.78 | CDK6 (0.51) | CDK6CCND1CDK1CDK4CCNA2 | |
| SCHEMBL20744015 | 0.78 | CCND1 (0.42) | CDK6CCND1CDK2CDK1CNR2 | |
| SCHEMBL29615722 | 0.76 | CCND1 (0.61) | CDK6CCND1CDK2CDK1CNR2 | |
| SCHEMBL18291458 | 0.76 | PDE9A (0.42) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | CDK6 2/4885CCND1 35/4885CDK2 3/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | CDK6 2/4885CCND1 34/4885CDK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.